Charles Schwab’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.45M | Buy |
360,160
+12,125
| +3% | +$116K | ﹤0.01% | 2490 |
|
|
2025
Q1 | $2.18M | Sell |
348,035
-5,003
| -1% | -$31.4K | ﹤0.01% | 2585 |
|
|
2024
Q4 | $2.87M | Buy |
353,038
+60,178
| +21% | +$489K | ﹤0.01% | 2563 |
|
|
2024
Q3 | $5.29M | Buy |
292,860
+6,990
| +2% | +$126K | ﹤0.01% | 2349 |
|
|
2024
Q2 | $2.94M | Buy |
285,870
+21,376
| +8% | +$220K | ﹤0.01% | 2572 |
|
|
2024
Q1 | $2.81M | Buy |
264,494
+1,970
| +0.8% | +$20.9K | ﹤0.01% | 2492 |
|
|
2023
Q4 | $2.4M | Buy |
262,524
+15,843
| +6% | +$145K | ﹤0.01% | 2556 |
|
|
2023
Q3 | $2.56M | Buy |
246,681
+67,811
| +38% | +$703K | ﹤0.01% | 2524 |
|
|
2023
Q2 | $2.56M | Buy |
178,870
+7,263
| +4% | +$104K | ﹤0.01% | 2474 |
|
|
2023
Q1 | $1.23M | Sell |
171,607
-1,647
| -1% | -$11.8K | ﹤0.01% | 2672 |
|
|
2022
Q4 | $1.94M | Buy |
173,254
+16,574
| +11% | +$186K | ﹤0.01% | 2579 |
|
|
2022
Q3 | $1.74M | Buy |
156,680
+36,866
| +31% | +$409K | ﹤0.01% | 2619 |
|
|
2022
Q2 | $1.01M | Sell |
119,814
-6,373
| -5% | -$53.8K | ﹤0.01% | 2794 |
|
|
2022
Q1 | $1.72M | Buy |
126,187
+2,888
| +2% | +$39.3K | ﹤0.01% | 2699 |
|
|
2021
Q4 | $2.43M | Buy |
123,299
+2,428
| +2% | +$47.8K | ﹤0.01% | 2636 |
|
|
2021
Q3 | $3.88M | Buy |
120,871
+13,751
| +13% | +$441K | ﹤0.01% | 2484 |
|
|
2021
Q2 | $3.63M | Buy |
107,120
+19,864
| +23% | +$673K | ﹤0.01% | 2504 |
|
|
2021
Q1 | $3.28M | Buy |
87,256
+11,358
| +15% | +$427K | ﹤0.01% | 2494 |
|
|
2020
Q4 | $2.52M | Buy |
75,898
+111
| +0.1% | +$3.69K | ﹤0.01% | 2532 |
|
|
2020
Q3 | $2.78M | Sell |
75,787
-5,881
| -7% | -$216K | ﹤0.01% | 2371 |
|
|
2020
Q2 | $2.69M | Buy |
81,668
+13,065
| +19% | +$430K | ﹤0.01% | 2311 |
|
|
2020
Q1 | $1.77M | Buy |
68,603
+816
| +1% | +$21.1K | ﹤0.01% | 2315 |
|
|
2019
Q4 | $2.11M | Buy |
+67,787
| New | +$2.11M | ﹤0.01% | 2400 |
|